A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder

NCT04786730 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention-deficit Hyperactivity Disorder

Interventions

DRUG: Centanafadine

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.